Association of time-to-intravenous furosemide with mortality in acute heart failure: data from REPORT-HF.
Diuretics
Heart failure
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
08
09
2022
received:
13
06
2022
accepted:
27
09
2022
pubmed:
6
10
2022
medline:
1
2
2023
entrez:
5
10
2022
Statut:
ppublish
Résumé
Acute heart failure can be a life-threatening medical condition. Delaying administration of intravenous furosemide (time-to-diuretics) has been postulated to increase mortality, but prior reports have been inconclusive. We aimed to evaluate the association between time-to-diuretics and mortality in the international REPORT-HF registry. We assessed the association of time-to-diuretics within the first 24 h with in-hospital and 30-day post-discharge mortality in 15 078 patients from seven world regions in the REPORT-HF registry. We further tested for effect modification by baseline mortality risk (ADHERE risk score), left ventricular ejection fraction (LVEF) and region. The median time-to-diuretics was 67 (25th-75th percentiles 17-190) min. Women, patients with more signs and symptoms of heart failure, and patients from Eastern Europe or Southeast Asia had shorter time-to-diuretics. There was no significant association between time-to-diuretics and in-hospital mortality (p > 0.1). The 30-day mortality risk increased linearly with longer time-to-diuretics (administered between hospital arrival and 8 h post-hospital arrival) (p = 0.016). This increase was more significant in patients with a higher ADHERE risk score (p In REPORT-HF, longer time-to-diuretics was not associated with higher in-hospital mortality. However, we did found an association with increased 30-day mortality, particularly in high-risk patients, and irrespective of LVEF or geographic region. ClinicalTrials.gov Identifier NCT02595814.
Identifiants
pubmed: 36196060
doi: 10.1002/ejhf.2708
pmc: PMC10099670
doi:
Substances chimiques
Diuretics
0
Furosemide
7LXU5N7ZO5
Banques de données
ClinicalTrials.gov
['NCT02595814']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
43-51Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Eur J Heart Fail. 2019 Oct;21(10):1187-1196
pubmed: 31419004
Eur Heart J. 2013 May;34(19):1404-13
pubmed: 23095984
JAMA Cardiol. 2020 Apr 1;5(4):401-410
pubmed: 31913404
Biometrics. 2001 Mar;57(1):120-5
pubmed: 11252586
Eur J Heart Fail. 2015 May;17(5):527-33
pubmed: 25754836
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Eur J Heart Fail. 2014 Dec;16(12):1283-91
pubmed: 25452165
Am Heart J. 2013 Aug;166(2):349-56
pubmed: 23895819
Eur J Heart Fail. 2022 Jan;24(1):4-131
pubmed: 35083827
Eur Heart J. 2021 Nov 14;42(43):4442-4451
pubmed: 34184057
Int J Cardiol. 2018 Oct 15;269:207-212
pubmed: 30041982
J Am Coll Cardiol. 2008 Aug 12;52(7):534-40
pubmed: 18687247
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
JAMA. 2005 Feb 2;293(5):572-80
pubmed: 15687312
JACC Heart Fail. 2018 Apr;6(4):286-294
pubmed: 29598933
Int J Cardiol. 2019 Jun 15;285:40-46
pubmed: 30905515
Circ Heart Fail. 2021 Apr;14(4):e007901
pubmed: 33866828
J Am Coll Cardiol. 2017 Jun 27;69(25):3042-3051
pubmed: 28641794
Lancet Glob Health. 2020 Mar;8(3):e411-e422
pubmed: 32087174
BMJ Open. 2014 Dec 30;4(12):e005988
pubmed: 25550294
Am J Cardiol. 2021 May 15;147:70-79
pubmed: 33617811
Eur J Heart Fail. 2015 Jun;17(6):544-58
pubmed: 25999021
JACC Heart Fail. 2018 Apr;6(4):295-297
pubmed: 29598934
Epidemiology. 2000 Sep;11(5):550-60
pubmed: 10955408
J Am Heart Assoc. 2019 Sep 17;8(18):e012282
pubmed: 31495302